hero image
Dr. Serhat Unal - International Federation on Ageing. Ankara, , TR

Dr. Serhat Unal Dr. Serhat Unal

Chair of Department of Infectious Disease | Hacettepe University

Ankara, TURKEY

Dr. Unal is the previous Dean of the School of Medicine and Chair of Department of Internal Medicine.







Prof. Dr. Serhat ÜNAL-İnfeksiyon Dünyası Çalıştayı




Dr. Unal is the previous Dean of the School of Medicine and Chair of Department of Internal Medicine. He is currently the Chair of Department of Infectious Diseases at Hacettepe University in Ankara, Turkey. Dr. Unal previously served as a Fellow in Infectious Diseases at the New England Deaconess Hospital and Harvard Medical School in Boston, MA. His main areas of interest are hospital infection control, antimicrobial resistance in gram positive cocci, adult vaccination, and HIV infection.
Dr. Unal has published 155 international articles and 160 international abstracts. He was honored with the Non-Governmental Organizations Women Health Commission Millennium Award in HIV/AIDS in 2002 and the Centenary Medal of the Polish Society of Internal Medicine in 2008. Dr. Unal is President of the Turkish Society of Internal Medicine, and Secretary General of Turkish Society of Hospital Infection and Control.

Areas of Expertise (5)


Infectious Diseases

HIV Infection

Hospital Infection Control

Adult Vaccination

Education (1)

Hacettepe University: M.D., Medicine

Languages (1)

  • English

Media Appearances (1)

Third Turk hospitalized for suspected MERS case -UPDATED

World Bulletin  online

“The virus causes more severe disease in people who already have chronic illnesses like diabetes, renal failure and lung disease,” says Professor Serhat Unal, head of the Internal Disease Department of Hacettepe University in Ankara.

view more

Featured Articles (5)

Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: A 2014 follow-up survey

International Journal of Antimicrobial Agents

2015 As a follow-up to our 2009 survey, in order to explore opinion and practice on the epidemiology and management of meticillin-resistant Staphylococcus aureus (MRSA) in Europe, we conducted a second survey to elicit current opinions on this topic, particularly around antibiotic choice, dose, duration and route of administration...

view more

Risk Factors and Antibiotic Use in Methicillin-Resistant Staphylococcus aureus Bacteremia in Hospitalized Patients at Hacettepe University Adult and Oncology Hospitals

Microbiology Bulletin

2014 The aim of this study was to evaluate methicillin-resistant Staphylococcus aureus (MRSA) bacteremia cases who were followed at the Infectious Diseases Unit of Internal Medicine Department, at Hacettepe University Adult and Oncology Hospitals between January 2004-December 2011...

view more

International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003-2012

Annals of Clinical Microbiology and Antimicrobials

2014 Device-associated healthcare-acquired infections (DA-HAI) pose a threat to patient safety, particularly in the intensive care unit (ICU). We report the results of the International Infection Control Consortium (INICC) study conducted in Turkey from August 2003 through October 2012...

view more

A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey

Journal of Antimicrobial Chemotherapy

1999 This study was carried out with the participation of eight hospitals in Turkey to determine the frequency of Gram-negative bacteria isolated in intensive care units (ICU) and to compare their resistance rates to selected antibiotics. Aerobic Gram-negative bacteria ...

view more

Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin

Antimicrobial Agents and Chemotherapy

1993 Quinolones have been reported to be active against Brucella species in vitro. In this prospective randomized study, the efficacy and safety of the combination of ofloxacin plus rifampin were compared with the efficacy and safety of doxycycline plus rifampin, ...

view more